Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients. - Wikidata - awgldk - TriplyDB

Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.

Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.

http://www.wikidata.org/entity/Q37615896

about

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report.Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC.

P2860

Q26775711-F367BFC0-9C84-4054-9DD1-60EC4B2C9D78 Q36337416-5B80E54A-6B00-418B-B6B0-2B5D40538CD1 Q36849652-84F50F9E-FC5B-4DA5-B66B-DB66D42A5E41 Q38930166-05E7E1F3-82E5-4847-B3AD-2C47720B47AE Q40081348-FD64CE6F-2196-4E6C-B8CC-E454A4E19FBF Q49164511-AF7396C1-C96E-4C87-A2B5-3622A7D9091C

P2860

Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.

http://www.wikidata.org/entity/Q37615896

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Panitumumab in Japanese patien ...... llance study of 3085 patients.

@en

Panitumumab in Japanese patien ...... llance study of 3085 patients.

@nl

type

label

Panitumumab in Japanese patien ...... llance study of 3085 patients.

@en

Panitumumab in Japanese patien ...... llance study of 3085 patients.

@nl

prefLabel

Panitumumab in Japanese patien ...... llance study of 3085 patients.

@en

Panitumumab in Japanese patien ...... llance study of 3085 patients.

@nl

P1433

Q37615896-F92EBD2D-DA6F-495B-827D-D6A010E0656B

P1476

Q37615896-804FD044-D2BD-44D2-96FE-6FC245290D59

P2093

Q37615896-2426DE70-1334-46A8-A1BC-E16B77F1A2CD

Q37615896-741EE1A4-EAFF-4FF2-9F5A-EE534F1EA3A4

Q37615896-773367EB-F427-4C78-9971-6211DBF5034B

Q37615896-8BF676B5-0AA8-40BC-A71E-96A5ED310557

Q37615896-AF61FEF4-18D9-4AC5-93FE-A24F292FF0B6

Q37615896-B68430EB-0FF2-4F26-82D3-6D0C56155C9A

Q37615896-C7890426-BBE7-49C3-9E87-FBF53E19B8A6

Q37615896-E07D8871-40FC-4F3F-97A6-077800409BC3

Q37615896-E4B0C0D7-D4B7-497A-8CE9-6F9C93923E5C

Q37615896-EB1236D9-7ACE-4462-BF50-84C6BDB9A2CE

P2860

Q37615896-24D9E1B4-EB44-463E-AB63-DC6A207EF144

Q37615896-2E5E5A8D-F8E8-4E27-940E-1EFD22203687

Q37615896-49F79E8B-0D4A-4EC2-BD66-47DBCCD16D18

Q37615896-4ED840DB-7561-4B01-88B8-150FDF31F17D

Q37615896-57EEB54B-87FE-4E25-9EA1-7C1EF2F257E1

Q37615896-59FD4EFF-7BC3-4FB8-8C22-5CE7F8557932

Q37615896-6614D6EC-BAF9-40B9-B266-093602388240

Q37615896-69EEB125-1089-4262-BCDC-A560678035A4

Q37615896-73E6518B-D72A-460C-A945-C881EFC47B7F

Q37615896-77C95A6D-A245-4B80-A22A-B06AA1ACD147

P304

Q37615896-CD10014A-69A2-48D6-B58C-C073D31BD41F

P31

Q37615896-EEADED1E-38A6-4E49-9610-69BD4C1F3532

P356

Q37615896-3CD443D9-201A-4B23-8C92-760D09548EFF

P433

Q37615896-7845EEF2-E222-488B-9A23-0A17A0AECD79

P478

Q37615896-3F064DBC-D7C2-4A69-BDFD-5B4C8573FF54

P577

Q37615896-D46825F3-8182-42B2-88A3-ABA4D575EB63

P5875

Q37615896-F1F986F5-2431-42B0-8C44-37F27C194EDE

P698

Q37615896-D8D00C43-1F8E-40AC-B3CC-350CDC21BE59

P921

Q37615896-60F27F1B-C62E-4421-ADD6-727705168900

P932

Q37615896-86ED93E3-5EE4-4099-B718-BCBCB22C1515

P356

P1433

Japanese Journal of Clinical Oncology

P1476

Panitumumab in Japanese patien ...... llance study of 3085 patients.

@en

P2093

Akihiko Gemma

http://www.w3.org/2001/XMLSchema#string

Atsushi Ohtsu

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ueno

http://www.w3.org/2001/XMLSchema#string

Ikuo Yana

http://www.w3.org/2001/XMLSchema#string

Kei Muro

http://www.w3.org/2001/XMLSchema#string

Kenichi Sugihara

http://www.w3.org/2001/XMLSchema#string

Kiyohiko Hatake

http://www.w3.org/2001/XMLSchema#string

Naoya Yamazaki

http://www.w3.org/2001/XMLSchema#string

Narikazu Boku

http://www.w3.org/2001/XMLSchema#string

Takayuki Yoshino

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer treatment and survivorship statistics, 2012

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cancer statistics, 2010

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Colorectal cancer molecular biology moves into clinical practice.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

P304

214-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYT196

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260196513

http://www.w3.org/2001/XMLSchema#string

P698

24526771

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3941645

http://www.w3.org/2001/XMLSchema#string